Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?
Candidate 20 Times More Potent Than Leqembi In Preclinical Studies
More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.
